DHT Blockers Explained: How Finasteride Stops Hair Loss at the Root

If you are losing hair and have looked into treatment options, you have almost certainly encountered finasteride. It is the most prescribed oral medication for androgenetic alopecia — the medical term for male pattern baldness — and for good reason: the clinical evidence for its effectiveness is among the strongest of any pharmacological hair loss treatment available. But understanding why finasteride works requires understanding DHT — the hormone doing the damage in the first place.

DHT: The Hormone Behind Hair Loss

Dihydrotestosterone (DHT) is a potent androgen derived from testosterone through the action of an enzyme called 5-alpha reductase (5-AR). The conversion occurs primarily in the skin, liver, and prostate, and DHT itself is a normal, physiologically important hormone — it drove many aspects of male development in utero and during puberty, including genital development and the growth of body and facial hair.

In scalp hair follicles, however, DHT is essentially destructive in genetically predisposed men. Scalp follicles in men with androgenetic alopecia have androgen receptors that are particularly sensitive to DHT. When DHT binds to these receptors, it initiates a process called miniaturization: the follicle progressively shrinks, producing shorter, finer, lighter hair with each successive growth cycle. Over a period of years — often a decade or more — miniaturized follicles produce hairs so thin they are cosmetically invisible, and eventually they become dormant altogether.

The miniaturization process follows a characteristic pattern — receding hairline at the temples and thinning at the crown — because the follicles in those regions are most genetically sensitive to DHT. Follicles at the back and sides of the scalp (the occipital and temporal regions) carry fewer androgen receptors and are largely DHT-resistant, which is why hair loss in androgenetic alopecia spares those areas and why hair transplant surgeons harvest follicles from those donor regions.

The Miniaturization Timeline

Hair miniaturization is a slow process, which is both its challenge and its treatment opportunity. The typical course of androgenetic alopecia in men involves:

• Early stage (Hamilton-Norwood I–II): Slight recession of the hairline at the temples. Often begins in the early-to-mid 20s in men with a strong genetic predisposition.
• Mid stage (Norwood III–IV): More pronounced temporal recession and emerging thinning at the crown. This is when most men first seek treatment.
• Advanced stage (Norwood V–VII): Merging of the frontal recession and crown thinning into a large bald area, with only a horseshoe band of hair remaining along the sides and back.

Because the process is slow and hormonal, it is most amenable to intervention early — when follicles are miniaturizing but still viable. DHT blockers halt the miniaturization process and can allow some already-miniaturized follicles to partially recover. They cannot resurrect follicles that have been dormant for years.

The fundamental message is this: the earlier you treat androgenetic alopecia, the better the outcome. Hair you are losing now can be retained; hair already long gone is unlikely to come back from medication alone.

How Finasteride Works: Blocking 5-Alpha Reductase

Finasteride is a type II 5-alpha reductase inhibitor. By competitively binding to the 5-AR type II enzyme (the predominant isoform in scalp follicles and prostate), finasteride prevents testosterone from being converted to DHT in those tissues. The result is a significant reduction in scalp and serum DHT levels.

At the 1 mg daily dose approved for hair loss:

• Scalp DHT levels are reduced by approximately 60–70%
• Serum (blood) DHT levels fall by approximately 65–70%
• Testosterone levels rise modestly (about 10–15%) because the conversion pathway to DHT is partially blocked

This is a fundamentally different mechanism from minoxidil, which works by directly stimulating follicle growth (through potassium channel opening and increased local blood flow) without addressing the hormonal cause. Finasteride addresses the underlying driver of the disease; minoxidil works around it.

Finasteride 1 mg vs. 5 mg: What's the Difference?

Finasteride is available in two doses: 1 mg (Propecia, generic) for hair loss and 5 mg (Proscar, generic) for benign prostatic hyperplasia (BPH). This confuses many patients who see both on pharmacy shelves.

Clinical trials established that 1 mg is the optimal dose for hair loss. Dose-finding studies demonstrated that going from 0.2 mg to 1 mg produced meaningful incremental DHT suppression in the scalp; going from 1 mg to 5 mg added relatively little additional suppression at the follicle level (DHT is already reduced by ~70% at 1 mg) while increasing systemic exposure and side effect risk.

Some providers prescribe 5 mg for hair loss off-label, particularly in patients with concurrent prostate enlargement, or cut 5 mg tablets into quarters as a cost-saving strategy. Both practices are clinically reasonable but should be discussed with your prescriber. For most men seeking hair loss treatment only, 1 mg daily is the appropriate target dose.

The Evidence: What Clinical Trials Show

Finasteride's efficacy for androgenetic alopecia is supported by some of the most rigorous trial data in hair loss medicine.

The pivotal trials referenced in FDA approval — often called the MCNEIL-PPC trials (conducted in two large Phase III studies) — enrolled over 1,800 men aged 18–41 with mild-to-moderate vertex and frontal hair loss. After two years of treatment with finasteride 1 mg daily:

• 87% of men on finasteride had slowed or halted hair loss compared to baseline (versus 23% of placebo-treated men)
• 66% of men on finasteride experienced visible hair regrowth at the vertex (crown), as assessed by standardized photography and hair counts
• Hair count increased by an average of 107 hairs per 1-inch-diameter circle at the vertex in the finasteride group, versus a decrease of 75 hairs in the placebo group

Five-year extension data from these trials showed that the benefits were maintained across the full study period, and that men who had been on placebo for two years and then switched to finasteride began experiencing the same regrowth trajectory — confirming that the drug's effect is ongoing and dependent on continued use.

Frontal hairline response is somewhat less robust than vertex response — the crown tends to respond better — but significant patient-reported satisfaction with frontal appearance was also documented.

Post-Finasteride Syndrome: Putting the Risk in Context

Any honest discussion of finasteride must address post-finasteride syndrome (PFS) — a collection of reported persistent sexual and neurological side effects that some patients attribute to finasteride use. These include persistent erectile dysfunction, reduced libido, depression, cognitive symptoms, and ejaculatory changes that reportedly continue after discontinuation of the drug.

PFS is a contentious area of medicine. The mainstream clinical position, supported by large randomized trial data and systematic reviews, is that:

• Sexual side effects (decreased libido, erectile dysfunction, reduced ejaculate volume) occur in approximately 1–2% of patients in placebo-controlled trials — and these rates are only marginally higher than placebo rates, suggesting a meaningful nocebo component
• In the vast majority of patients who experience side effects, they resolve within weeks of stopping the medication
• Persistent side effects after discontinuation — the defining feature of PFS — have not been reproducibly demonstrated in controlled clinical studies
• The FDA has required updated labeling acknowledging reports of persistent sexual dysfunction, while noting that causality has not been established

This does not mean patient reports of PFS are fabricated — it means the population-level clinical trial data does not support persistent adverse effects as a common or predictable outcome. Men with pre-existing sexual dysfunction, anxiety disorders, or high baseline anxiety about side effects may be at greater risk of experiencing side-effect concerns. Discussing your personal risk profile with your provider before starting finasteride is standard practice.

The benefit-risk calculus for most men with androgenetic alopecia is clear: a drug that halts hair loss in 87% of patients and produces regrowth in 66% carries a low but real risk of reversible sexual side effects in 1–2%, with rare reports of persistence that remain mechanistically unexplained. Most men find this acceptable; some do not, and that is a valid individual choice.

Combination Therapy: Finasteride + Minoxidil

The most effective pharmacological approach to androgenetic alopecia is combining finasteride (which addresses the hormonal cause) with topical or oral minoxidil (which directly stimulates follicle activity). Multiple clinical studies have demonstrated that the combination produces superior outcomes to either agent alone:

• A 2015 study in Dermatology and Therapy found that combination therapy produced significantly greater hair count increases and patient satisfaction at 12 months compared to either monotherapy
• Oral minoxidil at low doses (0.625 mg–2.5 mg daily) has emerged as a preferred combination partner in recent years, offering systemic follicle stimulation that complements finasteride's DHT suppression without the application inconvenience of topical solutions

For men serious about maintaining their hair over the long term, combination therapy started at the earliest sign of loss offers the best probability of meaningful preservation and partial regrowth. Hair loss treatment is not a one-time intervention — it is a long-term commitment that pays dividends in proportion to how early and consistently it is maintained.